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Abstract  
Background – Cardiovascular disease is the leading cause of morbidity and mortality worldwide 
and atherosclerosis is estimated to be the underlying cause of approximately 50% of all deaths 
in western societies. Many aspects of the atherosclerotic disease are still incompletely 
characterized; it is commonly believed that inflammation is the driving force in development 
and progression of the disease and lately here has been increasing interest in the possible 
interplay between hypoxia and inflammation as well as the renin-angiotensin system (RAS) 
and inflammation. 
Aim – To test the hypothesis that hypoxia leads to induction of the RAS, including angiotensin II 
receptor type 1 (AT₁), and that this results in increased inflammation in the atherosclerotic 
plaque. To investigate what cells would be involved in hypoxia-RAS interplay and to asses 
effects of RAS interfering drugs in hypoxic environments. 
Methods – Histological examination of human atherosclerotic plaques and comparative analysis 
of plaques and serum proteins in patients treated with RAS interfering drugs and controls. In 
vitro cell experiments conducted on primary human smooth muscle cells and macrophages 
where cells were exposed to hypoxia, angiotensin II and RAS interfering drugs. 
Results – Expression of AT₁ co localizes with expression of hypoxia marker HIF-1α in 
macrophage rich areas of atherosclerotic plaques. Statistical analysis proved strong correlation 
between expression of AT₁ and macrophage marker CD68 as well as between expression of 
HIF-1α and CD68. In vitro cell experiments confirmed expression of AT₁ in macrophages. 
Conclusions – This report presents evidence implicating hypoxia-RAS interplay via stabilization 
of the protein HIF-1α. Further experiments are required to elucidate what effect this interplay 
has on inflammatory profile of the atherosclerotic plaque. 
 Key words – Atherosclerosis, renin-angiotensin system (RAS), angiotensin II type 1 receptor 
(AT₁), hypoxia inducible factor-1α (HIF-1α), macrophages. 
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Background 
Cardiovascular disease is the leading cause of morbidity and mortality worldwide [1]. In this 
group of diseases we find conditions such as coronary artery disease and cerebrovascular 
disease; two common health problems, manifestations of which include myocardial infarction, 
heart failure and ischemic stroke. The underlying cause of these conditions is atherosclerosis, 
a disease of the large arteries characterized by the accumulation of lipids and fibrous elements 
in the vessel wall leading to the development of lesions known as atherosclerotic plaques or 
atheromata. Atherosclerosis is common and a major health problem in today´s western 
societies where it has been estimated to be the underlying cause of approximately 50% of all 
deaths [2]. 
 The pathogenesis of atherosclerosis is complex with many contributory 
factors. Formation of plaques starts with the accumulation of low density lipoproteins, LDL, 
in the inner most layer of the vessel wall (the intima). Trapped in the intima the LDL is 
subjected to various modifications, including oxidation. Accumulation of oxidized LDL leads 
to inflammation and subsequent recruitment of monocytes and T-cells [3, 4].  Recruited 
monocytes differentiate into macrophages that internalize the modified lipoproteins resulting 
in the formation of so called foam cells; which denote lipid loaded macrophages. As the 
atheroma progresses the foam cells are prone to undergo apoptosis or necrosis; as they die 
they deposit their lipid-filled contents in the tissue thus forming the necrotic core of the 
plaque [2]. Foam cells and T-cells will further the inflammatory response by secretion of 
cytokines and growth factors mediating smooth muscle cell (SMC) migration, proliferation 
and extracellular matrix production. This causes SMCs to migrate from the vessel media into 
the growing atheroma where they undergo a phenotype shift, from a contractile phenotype to 
a synthetic phenotype. These intimal SMCs then secrete extracellular matrix giving rise to the 
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fibrous cap, a layer of fibrous tissue encapsulating the core of the atheroma, resulting in a 
fibrous plaque [2, 5].  
With the accumulation of fibrous elements and smooth muscle cells the plaque 
grows; initially the lesion expands towards the outer wall of the vessel (the adventitia) but 
gradually it will start expanding inwards, encroaching on the vessel lumen. Though the plaque 
is now starting to occlude the vessel many of these lesions are still asymptomatic. 
Complications in form of myocardial infarction and ischemic stroke often occur when an 
atherosclerotic plaque ruptures leading to the formation of an occlusive thrombosis or 
subsequent embolus. How prone a plaque is to rupture, i.e. the vulnerability of the plaque, 
depends on a large number of factors; vulnerable plaques generally display a histological 
composition with an increased number of inflammatory cells and a thin fibrous cap [2]. 
Inflammation seems to be a driving force of plaque vulnerability.   
Our understanding of the process of atherogenesis (i.e. the formation of 
atherosclerotic plaques) has grown steadily over the years. Numerous works have highlighted 
the importance of inflammation in this process [1, 2, 4, 6-8] and it is commonly believed that 
inflammation is the driving force behind formation, progression and rupture of atherosclerotic 
plaque. Macrophages have been a natural area of interest in this matter. We know that 
macrophages are crucial in the atherogenic process, the differentiation of monocytes into 
macrophages in the intima is a prerequisite for development of atheromata [4]. There have, 
however, recently been implications that SMCs may also play an important part in the 
inflammatory process in atherosclerosis. It is possible that SMCs recruited to the 
atherosclerotic lesion may take on an inflammatory phenotype, secreting cytokines and 
expressing cell adhesion molecules [5]. In this area much is still unknown, but stimuli such as 
oxidized LDL and angiotensin II have been found to induce SMC secretion of Monocyte 
Chemotactic Protein-1 (MCP-1), Interleukin-6 (IL-6), IL-8 and Tumor Necrosis Factor α 
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(TNFα) [5]. It is possible that SMCs may play an important role in maintaining the 
inflammatory response in atherosclerosis. Still, on this matter, there are other contributory 
factors to be taken into account.  
In recent years we have gained an increased understanding of the importance of 
hypoxia (insufficient levels of oxygen in the tissue) in plaque formation and progression. 
Hypoxia is a common feature of the atherosclerotic tissue due to increased oxygen 
consumption and decreased oxygen supply. The foam cells formed in the early stages of 
athrogenesis are highly oxygen consuming [9], their accumulation leads to increased oxygen 
consumption and oxygen demand in the tissue. As the atherosclerotic plaque grows the vessel 
intima grows thicker. The intima relies on diffusion of oxygen from the blood flowing 
through the vessel lumen for its oxygen supply and the maximum diffusion limit is 
approximately 100–250 μm. The thickness of the plaque often exceeds 250 μm, indeed it can 
often reach a thickness many times as great, and as a result oxygen supply to the tissue is 
hampered [10].  This combination of increased oxygen consumption and decreased oxygen 
supply makes hypoxia a common feature of the atherosclerotic plaque (figure 1).  
 
 
 
 
 
 
 
 
 
Figure 1: Intimal thickening and foam cell accumulation resulting in hypoxia 
 
The intima depends on diffusion of 
oxygen from the vessel lumen for its 
oxygen supply; thickening will 
increase diffusion distance and 
hamper oxygen diffusion. 
Furthermore oxygen consuming 
foam cells will accumulate in the 
growing atheroma resulting in 
increased oxygen demand. Increased 
oxygen consumption and decreased 
oxygen supply will lead to hypoxia 
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Hypoxia has pronounced effects on many aspects of cell physiology [11, 12] and 
has been indicated as a key factor in the progression of atherosclerotic plaques to advanced 
lesions, by depletion of ATP (adenosine-tri-phosphate), promotion of lipid accumulation and 
increased inflammation [13]. The link between hypoxia and inflammation is incompletely 
characterized but evidence suggests that one of many important factors may be the protein 
hypoxia inducible factor 1α (HIF-1α). HIF-1α is one of two subunits forming the transcription 
factor hypoxia inducible factor 1 (HIF-1),the predominant mediator of responses to hypoxia in 
all cell types [14]. The limiting factor in HIF-1 formation is the supply of HIF-1α; under 
normoxic circumstances HIF-1α is subjected to hydroxylation and is subsequently rapidly 
degraded. Under hypoxic circumstances lack of oxygen prevents hydroxylation of HIF-1α 
from taking place and HIF-1 can be formed [12]. HIF-1α has been shown to mediate adaptive 
responses to tissue hypoxia [12], however in environments of chronic continuous hypoxia or 
chronic intermittent hypoxia HIF-1α mediates maladaptive responses and has been implicated 
in development of tissue inflammation [15]. Recent evidence suggests significant crosstalk 
between HIF-1α and the transcription factor nuclear factor kappa B (NF-κB) [15, 16] and that 
NF-κB may regulate hypoxia-mediated inflammatory responses [16, 17]  
 Recently there has also been increased interest in the role of the Renin-
Angiotensin-System (RAS) in the development and progression of atherosclerosis. The 
effecter molecule of the RAS is Angiotensin II, a protein formed by sequential enzymatic 
cleavage of angiotensinogen, a protein produced by the liver; this occurs both in the blood 
stream – circulation RAS, and in the tissue – tissue RAS (see figure 2). (R) Angiotensin II is a 
potent vasoconstrictor and the RAS is best known for its role in regulation of blood pressure, 
but lately attention has been directed to the RAS role in promoting atherosclerosis. 
Angiotensin II has been shown to directly stimulate SMC growth and production of 
extracellular matrix [2], important factors in development of fibrous lesions.   
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Furthermore, the RAS and angiotensin II have been frequently implicated as mediators of 
inflammation [18-21]; angiotensin II has been shown to increase vascular permeability and 
subsequent infiltration of inflammatory cells by mechanisms including cytokine release [22]. 
Current literature states that the main effect of the RAS on atherogenesis is mediated by its 
role in promoting hypertension, insulin resistance and vascular as well as systemic 
inflammation [23]. Furthermore it has been observed that elevated levels of tissue RAS 
components are present in atherosclerosis, independently of blood pressure elevation [18]. 
Interestingly drugs inhibiting the RAS has been shown to reduce inflammation by 
mechanisms independent of blood pressure [24]. Drugs inhibiting the RAS include both 
sartans, which act by blockade of the Angiotensin II type 1 receptor (AT₁) – also known as 
Figure 2: Angiotensinogen, 
formed by the liver, is 
sequentially cleaved to form 
Angiotensin II. 
Angiotensinogen is cleaved by 
renin forming Angiotensin I. 
Angiotensin I is the cleaved by 
Angiotensin Converting 
Enzyme (ACE) forming 
Angiotensin II. This process 
takes place locally in many 
tissues as well as in the blood 
stream. 
 
Figure 2: Schematic illustration of the RAS 
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angiotensin receptor blockers (ARB) – and Angiotensin-Converting-Enzyme-inhibitors 
(ACEi), which act by preventing formation of angiotensin II. 
 The interactions between hypoxia and the RAS have previously been addressed 
in the context of hypertension caused by periods of intermittent hypoxia in obstructive sleep 
apnea. It has been shown that exposure to intermittent hypoxia can increase arterial blood 
pressure in humans through RAS dependent mechanisms [25], one might argue that there 
seems to exist some sort of connection. This raises the question of a possible interaction 
between tissue hypoxia and the different components of the RAS locally in the atherosclerotic 
plaque. A question this study means to address. 
 
Aim  
This study means to address the possibility of interactions between hypoxia and the RAS in 
the process of atherogenesis; the hypothesis being that hypoxia leads to induction of the RAS 
and that this leads to increased inflammation in the hypoxic atherosclerotic plaque. As part of 
investigating this hypothesis the question of which cells that would mediate this possible 
proinflammatory effect will be addressed, the hypothesis being that SMCs, in addition to 
macrophages, may play an important part in mediating inflammation induced by angiotensin 
II. Furthermore, effects of angiotensin II type 1 receptor blockade will be assessed in the 
context of its possible effect modulating properties and anti-inflammatory effects in hypoxic 
environments, the hypothesis being that RAB treatment may alter the composition of the 
atherosclerotic plaque and reduce occurrence of proinflammatory molecules in vivo as well as 
in vitro.  
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Material and methods 
Histological examination of atherosclerotic plaques – and – comparative analysis of 
plaque morphology and serum markers of inflammation between patients receiving 
ARB treatment and controls  
Study population 
The study population consisted of 121 patients with symptomatic carotid stenosis recruited 
within the Gothenburg Atheroma Study Group. Patients were characterized with respect to 
medical history, physical examination, target organ damage and cardiovascular risk factors. 
Information was collected through a medical history questionnaire and examination of patient 
records. The study protocol was approved by the Ethical Committee of the University of 
Gothenburg and all participating subjects gave written informed consent. 
Study design 
To investigate plaque morphology histological examination of human atherosclerotic plaques 
was performed. 123 plaques were obtained from arteria carotis of the 121 patients constituting 
the study population. Stained sections were characterized with respect to expression of AT₁, 
hypoxia marker – HIF-1α, macrophage marker – CD68 and SMC marker – β-actin; 
furthermore localization of said expression was characterised. Analysis was performed to 
determine possible correlations between location as well as levels of expression. 
 To investigate effects of ARB treatment on plaque morphology 
and serum markers of inflammation in patients with atherosclerotic disease comparative 
analysis of different patient groups was performed. A retrospective cohort design was used. 
Two cohorts were defined, all patients in the study population receiving ARB treatment 
constituted the first (n=23); the second consisted of matched controls receiving no treatment 
interfering with the RAS, neither ARB nor ACEi (n=23). Controls were individually matched 
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for each subject in the exposed group. When matching consideration was taken to possible 
confounding factors, specifically: gender, age, diagnosed hypertension, diagnosed diabetes, 
previous and present smoking habits as well as treatment with statins and acetyl-salicylic-acid 
(ASA); table I show characteristics of patients used in comparative analysis. Comparison of 
plaque morphology and serum markers of inflammation was performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
  Table 1:   Characteristics of patients used for comparative analysis     
                
  Variable     ARB therapy     
        Yes (n=23)   No (n=23)   
                
  Women, n (%) 6 (26)   11 (48)   
  Age, years   68±14   68±12   
    mean   69   69   
    median   69   70   
  Clinical event         
    Stroke, n (%) 10 (43)   6 (26)   
    TIA*, n (%) 8 (35)   7 (30)   
    Amaurosis fugax, n (%) 5 (22)   10 (44)   
  Time since clinical event, days 124±114   105±77   
    mean   106   79   
    median   101   66   
  Hypertension, n (%) 22 (96)   19 (83)   
  Diabetes, n (%) 5 (22)   6 (26)   
  Previous smoker, n (%) 6 (26)   6 (26)   
  Current smoker, n (%) 3 (13)   3 (13)   
  ASA** therapy, n (%) 21 (91)   22 (96)   
  Statin therapy, n (%) 20 (87)   19 (83)   
  Blood pressure, mmHg         
    Systolic   155±25   160±40   
    Diastolic   80±10   80±20   
                
                
  * TIA = transient ischemic attack  ** ASA=acetyl-salicylic-acid      
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Atherosclerotic plaques 
123 atherosclerotic plaques from arteria carotis obtained during surgical endartherectomi (i.e. 
removal of the atherosclerotic plaque) were used for histological examination. Specimens 
were divided into 3 mm sections, fixed in formalin for 24 hours and embedded in paraffin 
before 4 µm thick sections were taken for immunohistochemistry. Sections were 
deparaffinised and antigens retrieved using DIVA Decloaker buffer (BioCare, Concord, CA, 
USA). Thereafter sections were washed with Tris-buffered saline buffer (TBS – a solution of 
0,20M Tris(hydroxymethyl)-aminomethane and 0,73M NaCl in Milli-Q H₂O, pH set to 6.8) 
and incubated with blocking buffer (TBS with addition of 0.1 % Tween and 1 % Bovine 
Serum Albumin (Sigma-Aldrich, St. Louis, Missouri, USA)) for 30 minutes before incubation 
with primary antibody in blocking buffer or DaVinci Green (PD 900 M) (Biocare Medical, 
California, USA)  for one hour. The samples were washed  before detection with MACH3 kit 
(M3M532 H)(Biocare Medical, California, USA) and subsequently washed again before 
detection with Vulcan Fast Red Chromogen kit 2 (FR805M) (Biocare Medical, California, 
USA). Sections were stained with Mayers hematoxylin for 45 seconds before dehydration. 
 Primary antibodies used were: for AT1 – mouse monoclonal Anti-Angiotensin 
II Type 1 Receptor antibody [1E10-1A9] (ab9391) (abcam, Cambrige Science Park, 
Cambrige, UK) at dilution 1:30 in DaVinciGreen (PD 900 M) (Biocare Medical, California, 
USA); for CD68 – lyophilized mouse monoclonal anti-CD68 (NCL-CD68-KP1) (Lecia 
Novocastra, Kista, Sweden) at dilution 1:500 in blocking buffer; for HIF-1α – mouse 
monoclonal anti-HIF-1 alpha antibody (ESEE122) (NB100-131) (Novus Biologicals, Atlanta, 
USA) at dilution 1:400 in DaVinciGreen (PD 900 M) (Biocare Medical, California, USA); β-
actin – mouse monoclonal anti-human Muscle Actin (M0635, IR700) (DAKO, Glostrup, 
Denmark) at dilution 1:400 in blocking buffer. 
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The BioPix 2.0 software (BioPix AB, Gothenburg, Sweden) was used to 
quantify expression of AT₁, HIF-1α, CD68 and β-actin in stained serial sections of carotid 
plaques. For each section the signal of interest was identified and the area of plaque were 
signal was found calculated; total plaque area was calculated and by dividing area of signal 
expression by total plaque area and multiplying by 100 the percentage of signal expression 
per plaque was attained.  
Furthermore, sections were characterized with respect to histological appearance 
and classified according to the American Heart Association (AHA) classification [26] as 
lesion type I-VI, where a higher number indicates a more advanced lesion. 
Serum samples 
Serum samples were collected from all patients and analyses of inflammatory markers were 
preformed. Analyzed parameters were: Ultra sensitive C-reactive Protein (U-CRP) by use of 
CRP High Sensitivity (981798) (Thermo Fischer Sientific, MA, USA); Monocyte 
Chemotactic Protein-1 (MCP-1) by use of Quantikine ELISA human CCL2/MCP-1 (DCP00) 
(R&D systems); IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, interferon-γ (IFN-γ) 
and tumor necrosis factor-α (TNF-α) by use of Human ProInflammatory 9-Plex Ultra-
Sensitive Kit (K15025C-1) (Meso Scale Discovery, Gaithersburg, Maryland, USA). 
 
In vitro examination of the effects of hypoxia and ARB treatment on expression of AT₁ 
and markers of inflammation in cell culture  
To elucidate the effects of hypoxia on the RAS and on inflammation at a cellular level, cell 
culture experiments were conducted on primary human aortic SMCs and primary human 
monocyte derived macrophages; these cell types were chosen as SMCs and macrophages 
were primarily considered to be the cells of interest.  
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Cell culture – smooth muscle cells 
Primary human aortic smooth muscle cells (Clonetics, Lonza, Basel, Switzerland) were 
cultured in Waymouth’s medium (Gibco, Invitrogen, Carlsbad, CA, USA) with 10% human 
serum, 10% fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mmol/L L-
glutamine. During experiments two different groups were used. The test group was 
challenged with incubation under hypoxic conditions (1% O2); Controls were incubated at 
normoxic conditions (21% O2). In both groups a subset of cells were incubated with the sartan 
Candesartan (Astra Zeneca AB, Södertälje, Sweden), an AT₁ - blocker, at the concentration of 
10ˉ⁷M. Experiments lasted for 24 hours before collection of medium and extraction of RNA. 
In total 4 experiments were conducted on cells of passage 2, 4, 5 and 6 respectively. 
Cell culture – monocyte derived macrophages 
Buffy coats were obtained from the local blood bank at Kungälv Hospital, Sweden, and 
human mononuclear cells were isolated by centrifugation in a discontinuous gradient of 
Ficoll-Paque (GE Healthcare). Cells were seeded in Macrophage-SFM medium (Gibco) 
containing granulocyte macrophage colony stimulating factor (GM-CSF). After 3 days, the 
medium was changed to RPMI medium without GM-CSF and cells were cultured for 6 days 
before experiments were started. During experiments cells were challenged with incubation 
under hypoxic conditions, controls were incubated under normoxic conditions; in both the 
hypoxic test group and the normoxic control group a subset of cells were stimulated with 
either angiotensin II or Candesartan. Experiments lasted for 24 hours before collection of 
medium and extraction of RNA. 
Real time reverse transcriptase polymerase chain reaction (Real Time RT-PCR) 
RNA was isolated from SMCs and macrophages with the RNeasy Mini Kit (Qiagen, 
Valencia, CA, USA). For SMCs expression of AT₁, HIF-1α and β-actin mRNA was 
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determined, for macrophages expression of AT₁ and β-actin mRNA was determined. For 
analysis all parameters were normalized to β-actin mRNA expression. The reverse 
transcription reaction was set up using a cDNA reverse transcription kit (#4368814, Applied 
Biosystems, Foster City, CA, USA) and performed with a Gene Amp PCR system 9700 
(Applied Biosystems, Foster City, CA, USA). Real time PCR amplification was set up using 
Taq man gene expression assays for AT₁ (Hs99999095_m1), HIF-1α (Hs 00153153_m1) and 
ActB (Hs99999903_m1) respectively, in combination with TaqMan Universal PCR master 
mix (#4324018) (Applied Biosystems, Foster City, CA, USA) and performed for 40 cycles on 
an ABI PRISM 7700 sequence detection system. 
Enzyme-linked immunosorbent assay (ELISA) 
Secreted cytokines were analyzed in medium from cultured primary human SMCs. Analysis 
of GM-CSF, interferon- γ (IFN-γ), Interleukin-1β (IL-1β), IL-10, IL-12 p70, IL-2, IL-6, IL-8, 
Tumor necrosis factor- α (TNF-α) and IL-18 was performed using Human ProInflammatory 
9-Plex Ultra-Sensitive Kit (K15025C-1) (Meso Scale Discovery, Gaithersburg, Maryland, 
USA) and Human IL-18 ELISA Kit (7620) (MBL, Woburn, USA) according to 
manufacturer’s instructions. Furthermore analysis of C-reactive protein (CRP), Intercellular 
Adhesion Molecule-1 (ICAM-1), Serum Amyloid A (SAA) and Vascular Cell Adhesion 
Molecule-1 (VCAM-1) was performed using Human Vascular Injury II Kit (K15136C-1) 
(Meso Scale Discovery, Gaithersburg, Maryland, USA) according to manufacturer’s 
instructions. 
Analysis for secreted components of the RAS (Angiotensin II and ACE) was 
performed using Angiotensin II Human/Rat ELISA (RA05880R) (BioVendor) and Human 
ACE Immunoassay (DACE00) (R&D Systems) according to manufacturer’s instructions. 
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Western Immunoblotting 
To investigate the occurrence of the protein AT₁ in macrophages Western Immunoblotting 
technique was used. As the AT₁ protein and the β-actin protein were suspected to be 
approximately the same size (40-45 kDa and 42 kDa respectively) sequential analysis was 
used starting with detection of AT₁ followed by detection of β-actin.  
Primary human monocytes exposed to hypoxia  or normoxia were used. 
Samples and ladder were loaded onto NuPAGE 4-12% Bis-Tris Gel 1.0mm X 10 well 
(Invitrogen, Carlsbad, CA, USA) along with loading buffer (a solution of 50mM 
Tris(hydroxymethyl)-aminomethane, 50mM dithiothreitol and 315mM sodium dodecyl 
sulfate in Milli-Q H₂O 10% glycerol and 0,005% bromphenol blue) and separated by 
electrophoresis at 200V for one hour. Proteins were subsequently transferred by electro 
transfer at 30V for one hour to Immuno-Blot polyvinylidene fluoride (PVDF) membrane 
(162-0177) (Bio-Rad, California, USA) using NuPAGE Transfer Buffer 20X (Invitrogen, 
Carlsbad, CA, USA). The membrane was thereafter washed with TTBS (TBS with addition of 
0.1 % Tween 20) and incubated in blocking buffer (TTBS with addition of 5 % non fat dry 
milk) over night at 4°C. Following day the membrane was washed with TTBS before 
incubation with primary antibody in antibody solution (TTBS with addition of 2 % non fat 
dry milk) for one hour at room temperature with gentle shaking. For primary antibody mouse 
monoclonal Anti-Angiotensin II Type 1 Receptor antibody [1E10-1A9] (ab9391) (abcam, 
Cambrige Science Park, Cambrige, UK) was used at dilution 1:400. The membrane was 
washed and incubated with secondary antibody in antibody solution for one hour at room 
temperature with gentle shaking. For secondary antibody sheep anti-mouse IgG, peroxidase-
linked speies-specific whole antibody (ECL) NA931(GH healthcare life sciences, Little 
Chalfont, UK) was used at dilution 1:5000. After washing, AT₁ was detected using 
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chemiluminiscence reaction with Immobilon Western Chemilumiscent HRP Substrate 
(WBKLS0500) (Merck Millipore, Billerica, USA).  
 After detection of AT₁ the membrane was stripped from antibodies by 
incubation with 0.2M NaOH solution for one hour at room temperature. After washing, the 
membrane was incubated in blocking buffer for one hour at room temperature with gentle 
shaking. There after detection of β-actin was performed by following the same protocol as for 
AT₁ and by use of primary antibody: rabbit polyclonal anit-actin A2066 (Sigma-Aldrich, St. 
Louis, Missouri, USA) at dilution 1:1250; and secondary antibody: Goat polyclonal anti-
rabbit IgG – H&L (HPR) (ab6721) (abcam, Cambrige Science Park, Cambrige, UK) at 
dilution 1:3000. 
 
Statistics 
Data are plotted as mean and SEM unless stated otherwise.  All analyses were performed 
using GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego California 
USA); a 95% confidence interval was used and P-values ≤ 0.05 were considered significant. 
Differences between groups were determined using non-parametric two tailed T-test (Mann-
Whitney two tailed T-test). Correlations between groups were determined using non-
parametric two tailed correlation (Spearman two tailed correlation). 
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Results 
Expression of AT₁ co localizes with CD68 positive macrophages and HIF-1α expression 
in human carotid atherosclerotic plaques 
Examination of carotid plaques proved expression of AT₁ to be co localized with expression 
of CD68, a protein used as a macrophage marker, and with expression of HIF-1α, a protein 
expressed under hypoxic conditions. No similar association was seen with β-actin, used as a 
marker of SMCs. As can been seen in figures 3 and 4 signals on AT₁-stained sections appear 
to coincide with signals on CD68 and HIF-1α stained sections.  
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Figure 3: Serial sections of an atherosclerotic plaque 
 
3A: Section of a human atherosclerotic 
plaque from arteria carotis stained for 
expression of AT1. Pictures 3B-D 
shows enlargement of the marked area 
of the plaque. 
3B: Three times magnification of area  
of AT1 expression in the plaque  
pictured in 3A. 
3C: Three times magnification of area 
of CD68 expression in the plaque 
pictured in 3A. 
3D: Three times magnification of area 
of HIF-1α expression in the plaque 
pictured in 3A. 
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Figure 4: Serial sections of an atherosclerotic plaque  
 
4A: Section of a human atherosclerotic 
plaque from arteria carotis stained for 
expression of AT1. Pictures 4B-D 
shows enlargement of the marked area 
of the plaque. 
4B: Two times magnification of area  
of AT1 expression in the plaque  
pictured in 4A. 
4C: Two times magnification of area 
of CD68 expression in the plaque 
pictured in 4A. 
4D: Two times magnification of area 
of HIF-1α expression in the plaque 
pictured in 4A. 
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Significant correlation between CD68 and AT₁ expression as well as HIF-1α and CD68 
expression in human carotid atherosclerotic plaques 
Expression of AT₁, CD68 and HIF-1α was quantified as percentage of expression per total 
plaque area. Subsequent correlation analysis proved significant correlation between CD68 and 
AT₁ expression: p < 0.0001, Spearman R = 0.4252 (fig. 5). As well as between HIF-1α and 
CD68 expression: p = 0.0097, Spearman R = 0.2393 (fig. 6). 
Figure 5: Correlation between expression of CD68 and AT₁ 
 
 
 
 
 
 
Levels of CD68 expression and AT₁ expression plotted against each other with CD68 
expression in percent on the X-axis and AT₁ expression in percent on the Y-axis. 
Correlation analysis using Spearman two tailed correlation revealed significant correlation: 
p < 0.0001, 95% confidence interval 0.2566 to 0.5687, Spearman R = 0.4252 
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Similar plaque morphology and levels of serum markers of inflammation in ARB 
treated patients and controls 
Statistical analysis of collected patient and plaque data revealed no statistically significant 
differences between the patient groups. Figure 7 shows differences in expression of AT₁, HIF-
1α, CD68 and β-actin between groups illustrated as fold change were the mean expression, of 
Figure 6: Correlation between expression of HIF-1α and CD68 
 
 
 
 
 
 
Levels of HIF-1α expression and CD68 expression plotted against each other with HIF-1α 
expression in percent on the X-axis and CD68 expression in percent on the Y-axis. 
Correlation analysis using Spearman two tailed correlation revealed significant correlation: 
p = 0.0097, 95% confidence interval 0.05405 to 0.4085, Spearman R = 0.2393 
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each protein respectively, in the control group was set to one and then compared to the 
expression in the ARB treated group. Distribution of morphological parameters between 
groups is also shown in table II.  Figure 8 shows levels of serum markers of inflammation 
illustrated as fold change were the mean level, of each protein respectively, in the control 
group was set to one and then compared to the expression in the ARB treated group. 
Distribution of serum markers of inflammation between groups is also shown in table III. 
Figure 7: Differences in expression of AT₁, CD68, HIF-1α and β-actin between 
studied groups 
 
 
 
Comparison of plaque morphology. The diagram shows differences in expression of 
AT₁, CD68, HIF-1α and β-actin between ARB treated patients and controls. Differences 
are illustrated as fold change. No statistically significant differences were found. 
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  Table II: Distribution of morphological parameters between studied groups   
                
  Variable     ARB therapy     
        Yes (n=24*) No (n=24*) 
                
     AHA-class            
    class 3, n (%) 2 (8)   1 (4)   
    class 4, n (%) 7 (29)   9 (39)   
    class 5, n (%) 4 (17)   2 (8)   
    class 6, n (%) 11 (46)   9 (39)   
                
  Area of AT₁ expression (%)         
    mean   0,72   0,71   
    medaian   0,54   0,56   
    standard deviation 0,52   0,55   
                
  Area of CD68 expression (%)         
    mean   1,46   2   
    medaian   1,39   0,82   
    standard deviation 1,12   2,9   
                
  Area of HIF-1α expression (%)         
    mean   2,92   2,57   
    medaian   2,24   1,32   
    standard deviation 2,21   3,3   
                
  Area of β-actin expression (%)         
    mean   4,29   4,58   
    medaian   3,56   3,74   
    standard deviation 3,79   3,65   
                
                
  * There were 23 patients in both groups; in each group one patient contributed  
    two plaques, from both the left and right carotid artery.     
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Figure 8: Differences in serum markers of inflammation between studied groups 
 
Comparison of serum markers of inflammation. The diagram shows differences in serum 
markers of inflammation between ARB treated patients and controls. Differences are 
illustrated as fold change. No statistically significant differences were found.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
Table III: Distribution of serum markers of inflammation between studied groups   
                
Group U-CRP TNF-α MCP-1 IFN-γ IL-1β IL-2 
ARB             
  Mean 2,04 3,46 264,76 0,54 0,28 0,17 
  Median 1,4 3,06 176,7 0,28 0,22 0,13 
  SD 1,78 1,4 380,54 0,93 0,23 0,15 
                
Controls             
  Mean 3,43 3,37 280,62 0,5 0,39 0,19 
  Median 2,03 3,09 267,56 0,29 0,32 0,16 
  SD 4,68 1,21 121,11 0,83 0,3 0,18 
                
Group   IL-5 IL-8 IL-12 IL-13 IL-4 IL-10 
ARB             
  Mean 0,35 3,55 1,31 2,24 0,07 1,05 
  Median 0,28 3,53 0,63 1,03 0,05 0,54 
  SD 0,26 0,93 2,65 3,23 0,07 1,41 
                
Controls             
  Mean 1,24 3,63 2,93 2,39 0,1 1,72 
  Median 0,31 3,36 0,45 1,13 0,03 0,83 
  SD 3,05 1,58 9,34 4,47 0,16 3,31 
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SMC cell-culture experiments proved inconclusive as to the effects of hypoxia and ARB 
treatment on AT₁ mRNA expression 
Real Time RT-PCR was used to detect expression of AT₁ mRNA in SMCs exposed to 
hypoxia, hypoxia in combination with ARB, normoxia and normoxia in combination with 
ARB respectively. No significant effects of exposure to neither hypoxia nor ARB were 
detected when all results were put together. Results varied notably between experiments 
conducted on cells of different passage; figure 9 shows the results of measurements from the 
first and last experiments respectively; as can be seen exposure to hypoxia and Candesartan 
lead to increased AT₁ mRNA expression in experiment one (fig. 9A) and to decreased AT₁ 
mRNA expression in experiment four (fig. 9B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Differences in AT₁ mRNA expression in SMC experiments 
         9A: SMC experiment 1                                         9B: SMC experiment 4 
 
Primary human aortic smooth muscle cells were used. Diagrams show differences in AT₁ mRNA 
expression between experiments conducted on cells of different passage. Cells in experiment 1 were 
of passage 2 (shown in 9A); cells in experiment 4 were of passage 6 (shown in 9B). When 
analyzing, levels of AT₁ expression was normalized to levels of β-actin expression. 
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Expression of HIF-1α mRNA was reduced in SMCs exposed to hypoxia 
Real Time RT-PCR was used to detect expression of HIF-1α mRNA in SMCs exposed to 
hypoxia, hypoxia in combination with ARB, normoxia and normoxia in combination with 
ARB respectively. In all four experiments expression of HIF-1α mRNA was reduced by 
exposure to hypoxia; exposure to Candesartan induced no difference in HIF-1α mRNA 
expression. Results are shown in figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Difference in HIF-1α mRNA expression between SMCs exposed to hypoxia 
and normoxia 
 
 
Diagram shows differences 
in HIF-1α mRNA 
expression between SMCs 
exposed to normoxia and 
hypoxia respectively. As 
can be seen exposure to 
hypoxia markedly reduced 
expression of HIF-1α 
mRNA. When analyzing, 
levels of HIF-1α expression 
was normalized to levels of 
β-actin expression. 
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No change in secretion of cytokines, ACE or angiotensin II from SMCs exposed to 
hypoxia or Candesartan compared to controls 
ELISA was used to analyze levels of proinflammtory substances in medium from SMC cell-
culture experiments. No significant differences could be seen between medium from different 
groups of cells; though, as with expression of AT₁ mRNA, occurrence of proinflammatory 
substances varied notably between experiments conducted on cells of different passage (not 
shown). 
 Analysis of secreted components of the RAS proved low levels of ACE and 
angiotensin II in all examined samples. No effect was seen of exposure to hypoxia or 
Candesartan.  
 
Macrophage cell-culture experiments proved inconclusive as to the effects of exposure to 
hypoxia, angiotensin II or Candesartan in AT₁ mRNA expression 
Real Time RT-PCR was used to detect expression of AT₁ mRNA in primary human monocyte 
derived macrophages; cells had been incubated at either hypoxia or normoxia and a subset of 
cells in environments were treated with angiotensin II or Candesartan. No significant effects 
of exposure to hypoxia, angiotensin II or Candesartan were detected. In 21 out of 24 samples 
mRNA levels were too low as to be determined. In the three samples that contained sufficient 
levels too be detected cycle threshold (CT) levels were high, average 42 and 50 cycles were 
used for detection. 
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Expression of AT₁ protein in macrophages verified with Western Immunoblotting 
As expression of AT₁ in macrophages could not be shown by analysis of mRNA expression 
with Real Time RT-PCR, Western Immunoblotting was performed to verify the expression of 
the AT₁ protein. As can be seen in figure 11A a clear signal was found  
corresponding to a protein size of approximately 60 kDa, which is consistent with expected 
size of the AT₁ protein (approximately 40,45 or 60 kDa depending on the glycosylation of the 
protein) . Figure 11B shows detection of β-actin on the same membrane after stripping of the 
AT₁ antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Detection of AT₁ protein and β-actin protein in human monocyte derived 
macrophages by Western Immunoblotting 
 
 
 
Here shown is the detection of AT₁ protein (11A) and β-actin protein (11B) in primary human 
monocyte derived macrophages by Western immunoblotting. The same membrane was stained 
for detection of AT₁ and subsequently stripped of antibodies before staining for β-actin. 
 
11A: Detection of AT₁ 
 
 
 
 
11B: Detection of β-actin 
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Discussion  
In summary, the main findings related in this thesis are: the observation that expression of 
AT₁ co-localizes with expression of HIF-1α (a marker of hypoxia) in macrophage rich areas 
of human atherosclerotic plaques, and the discovery of correlation between expression of 
CD68 and AT₁ as well as HIF-1α and CD68 in the human atherosclerotic plaque. Verification 
of expression of AT₁ protein in primary human monocyte derived macrophages by Western 
immunoblotting further supports these findings.  
Comparative analysis of the effects of ARB treatment on histological 
appearance of carotid atherosclerotic plaques and markers of inflammation in serum samples, 
performed on a study population consisting of patients with symptomatic
*
 atherosclerotic 
disease, proved no conclusive evidence supporting the hypothesis that ARB treatment would 
affect the composition of the plaque and the occurrence of proinflammatory proteins in vivo. 
Investigation of the potential role of SMCs in mediating hypoxia induced up regulation of the 
RAS and subsequent inflammatory responses proved no conclusive evidence supporting the 
hypothesis that hypoxia leads to induction of the RAS and that this leads to increased 
inflammation nor for the hypothesis that exposure to ARB would decrease occurrence of 
proinflammatory molecules in vitro. 
 Related results indicate that the primary cell type involved in RAS-inflammation 
interplay in the atherosclerotic plaque would be macrophages. The co localization of 
macrophages and expression of AT₁ in sections of atherosclerotic plaques has been previously 
observed by others [27] and furthermore, other components of the RAS, such as ACE and 
angiotensin II, have been found to be similarly expressed mainly in macrophage rich areas of 
the plaque [27, 28]. In this thesis it is further observed that the macrophage rich areas 
expressing AT₁ are also high in HIF-1α expression; this would indicate that hypoxia may have 
                                                          
*
 Symptomatic being defined as occurrence of transitory ischemic attack (TIA), amaurosis fugax or stroke 
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a part in inducing AT₁ expression in macrophages via stabilization of HIF-1α. This scenario 
does not appear to be entirely farfetched as others have shown that hypoxia induces 
expression of AT₁ in a HIF-1α dependent manner in other primary human cells, namely 
pulmonary fibroblasts [29]. 
Methodological considerations – problem analysis 
Comparative analysis of histological plaque appearance and serum markers of inflammation 
were unable to establish any differences between patients treated with ARB and patients 
receiving neither ARB nor ACEi treatment. This does not correspond well with other findings 
that indicate that differences in inflammatory profile and plaque character does exist [24, 30]. 
However, our study contains a number of weaknesses that need to be addressed that might 
explain these discrepancies. Firstly: our control group consisted of patients with symptomatic 
atherosclerotic disease, which means to say they have all shown clinical manifestations of 
unstable plaques; it is therefore unlikely that any difference in AHA class should be 
observable. And as most unstable plaques display similar morphological features it is unlikely 
that we should be able to detect any differences regarding histological appearance; it is 
possible that small differences in plaque morphology does exist between the two studied 
groups but the methods available for analysis are far to blunt for any small differences to be 
detectable. The problem with the control group is however not very easy to get around, 
assuming the study involves examination of atherosclerotic plaques. It is not ethically 
justifiable to imperil asymptomatic patients by subjecting them to possibly lethal surgery; this 
makes it difficult to retrieve plaques from asymptomatic patients. If one should only wish to 
study ARB effect on serum markers it would however not be unmanageable to acquire a more 
suitable control group. Or one can of course study plaque morphology indirectly by 
examining occurrence of clinical manifestations indicating vulnerable plaques; to study this 
one would ideally use a prospective cohort trial. Secondly: we used small cohorts which make 
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it further unlikely that any small differences would become apparent. Thirdly: no 
consideration was taken to the time of ARB treatment. The statistical material collected 
simply states whether or not the patient received ARB treatment at the time of the study. The 
same is true for the statistical data on most of the possible confounders that were considered. 
Ideally information on exposure to different drugs and risk factors would be more detailed. 
Finally: we must also consider the fact that our patients were not randomized to specific 
treatments. It is therefore likely that the selection of patients to treatment may be a 
confounding factor in our study.  In summary: the comparative study of ARB treatment effect 
on plaque morphology and serum markers of inflammation was not ideally designed and 
perhaps it is not surprising that it proved inconclusive. 
 The experiments conducted on primary human aortic SMCs proved difficult to 
interpret due to the substantial differences in outcome between the different experiments, 
indeed, outcomes of the first and the last experiments were completely opposite (fig. 9). 
However, we must consider the fact that the environment in cell culture differs widely from 
the one of the human aorta in vivo. It is well known that cells taken from their natural habitat 
and placed in culture will adapt to the new environment; from literature we know that SMCs 
possesses a high level of plasticity and are prone to change their phenotype in response to 
outer stimuli [5]. It would not seem unlikely that the reason for the varying outcomes to our 
experiments is the fact that the cells were of different passage in each experiment. 
Considering that cells of a lower passage are most likely possessed a phenotype similar to that 
of SMCs in vivo our conclusion was that the results of the first experiment (cells of passage 2) 
are likely to be the most reliable ones; this indicates that the clear trend seen in the first 
experiment, i.e. that expression of AT₁ is induced by Candesartan and further induced by 
hypoxia, might be worth investigating. However no similar trend could be found for secreted 
proinflammatory substances when analyzing the results of ELISA analysis of medium from 
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the first SMC experiment. Our results show no indication that the increased AT₁ expression 
would lead to increased secretion of proinflammatory substances; however, this might 
possibly be explained by lack of angiotensin II stimuli. Others have shown that angiotensin II 
can stimulate SMC proliferation and migration as well as expression of IL-18 receptor [5]. It 
is possible that new experiments, conducted on cells not exposed to cell culture environment 
for too long, were cells are stimulated with angiotensin II would prove interesting in further 
elucidating the possible role of SMCs in hypoxia-RAS-inflammation crosstalk. 
 When analyzing outcome of the SMC experiments we meant to 
use Real Time RT-PCR detection of HIF-1α mRNA to establish that the cells were indeed in a 
hypoxic state; however expression HIF-1α mRNA was consequently lower in cells exposed to 
hypoxia (fig. 10). We know that hypoxia stabilizes HIF-1α by preventing proteosomal 
degradation of the protein [12], so most likely expression of the HIF-1α protein is increased in 
the SMCs subjected to hypoxia – though we cannot be sure as we did not investigate this. 
Supposing HIF-1α protein levels are higher in SMC subjected to hypoxia this would correlate 
with a decrease in HIF-1α mRNA, which in turn would suggest some kind of negative 
feedback regulation of HIF-1α mRNA synthesis by the HIF-1α protein or other mechanisms 
related to hypoxia. This might be something worth investigating but the value of such an 
investigation in elucidating potential interactions between hypoxia and the RAS is 
questionable. But what we can learn from this is that we cannot rely on Real Time RT-PCR 
quantification of HIF-1α mRNA expression to establish that cells are expressing a hypoxic 
phenotype; perhaps detection of the HIF-1α protein by, for example, western immunoblotting 
would better serve this purpose.  
Western immunoblotting confirmed that macrophages do indeed express AT₁, 
results consistent with those of others [31]; but unlike many others we did not succeed in 
conclusively establish AT₁ mRNA expression in macrophages in Real Time RT-PCR analysis. 
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The fact that we were unable to detect AT₁ mRNA but were able to detect the AT₁ protein 
with Western immunoblotting lead us to believe that the primer we used for Real Time RT-
PCR might not be suitable to use in experiments conducted on primary human monocyte 
derived macrophages. For potential future experiments one could try using another primer that 
has been found adequate in similar situations by others, for example Guo F. et al [31]. We 
also feel that, just as with the SMCs, one has to be aware of the fact that the macrophages we 
conduct our experiments on are exposed to conditions that widely differs from the conditions 
found in the human body and in the atherosclerotic plaque. One could try to minimize the 
confounding effect this has by producing an environment more similar to the one of the 
atherosclerotic plaque. In this study we used angiotensin II to stimulate macrophages; 
angiotensin II has been shown to induce several components of the RAS, including AT₁ [27, 
31]. It might of course seem strange to use a substance know to induce increased expression 
of AT₁ when expression of AT₁ is the very thing we aim to study; but since our primary 
interest lies in finding out how hypoxia effects AT₁ expression this might not be a big 
problem. If our hypothesis holds true and hypoxia does induce increased expression of AT₁ 
this should be detectable even if cells are treated with angiotensin II. Other stimuli that might 
be used could be inducers of inflammation, for example lipopolysacaride (LPS) and hypoxia. 
Another possible solution to the fact that we were unable to detect sufficient levels of mRNA  
might be to adjust the Real Time RT-PCR method used; possibly increasing the number of 
cycles used for detection would prove helpful. 
In summary 
We set out to investigate the possibility of interactions between hypoxia and the RAS in the 
process of atherogenesis as well as what cells would seem to participate in such an 
interaction. Histological examination of human atherosclerotic plaques proved very useful in 
this task; and we now feel we have clear indications suggesting that such an interaction does 
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exist and that the primary cells of interest are macrophages. In vitro cell-culture experiments 
did however not prove very useful; though we now have a clear idea of how experiments may 
be improved for future research.  
We also wished to evaluate effects of ARB drugs in hypoxic environments. It is 
likely the study population used for this comparative analysis was too small to detect any 
differences in plaque morphology. As to the question of ARB effects on systemic 
inflammation measured as serum markers of inflammation we can in retrospective see that our 
patient material was not ideal for addressing this question; as earlier stated another study 
design using a different study population should probably be used to address this question. 
Cell culture experiments could prove helpful in further addressing our questions and, as 
previously stated, we now have a clear idea of how experiments may be improved for future 
research. 
Future studies 
There is need for further studies to fully understand the implications of hypoxia in the 
atherosclerotic tissue and in what way the RAS is involved in mediating hypoxia induced 
effects. We would like to continue investigating the potential interplay between hypoxia and 
the RAS in macrophages as we feel this might prove useful in furthering our understanding of 
atherogenesis. The hypothesis we intend to address is that hypoxia leads to induction of the 
RAS and that this leads to increased inflammation, and we now feel we should focus our 
interest on macrophages. The first step would be to establish if AT₁ expression in 
macrophages is in fact increased by exposure to hypoxia and that this does in fact result in 
increased inflammation. We hope to be able to conduct new in vitro experiments using 
primary human monocyte derived macrophages and stimulate them in different ways to 
mimic the environment of the atherosclerotic plaque. Thereafter we hope to be able to detect 
expression of AT₁ mRNA with Real Time RT-PCR, using an adjusted protocol, and 
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subsequently quantify expression. Medium from cell experiments would be examined for 
occurrence of pro-inflammatory substances and quantification of said substances preformed 
by use of ELISA. If we can establish that our hypothesis holds true we can then examine 
potential ways of preventing hypoxia induced inflammation mediated by the RAS.  
 
Conclusions and Implications 
In this thesis it is concluded that angiotensin II receptor type 1 is expressed in hypoxic, 
macrophage rich areas of the human atherosclerotic plaque; this conclusion was made by 
histological examination of atherosclerotic plaques. This is further supported by the finding 
that levels of AT₁ expression are significantly correlated to CD68 expression ***, and that 
levels of HIF-1α as well are correlated to CD68 expression **. This might perhaps lead to 
increased interest in investigating the role of hypoxia in atherogenesis which might in turn 
lead to important advances in our understanding of this complex process that is the underlying 
cause of approximately 50% of all deaths in today’s western society.  
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Populärvetenskaplig sammanfattning 
järt-kärlsjukdom är den ledande orsaken till död och sjuklighet i dagens 
samhälle [1]; åderförkalkning, på medicinskt fackspråk kallat ateroskleros, är 
den underliggande orsaken till många manifestationer av hjärt-kärlsjukdom och 
har uppskattats vara orsak till ungefär 50 % av alla dödsfall i vårt västerländska samhälle [2]. 
Ateroskleros är en sjukdom som karakteriseras av bildandet av plack i kroppens blodkärl, det 
är en långsam process som drabbar de flesta av oss så småningom. Det hela börjar med att 
LDL-kolesterol (populärt kallat ”det onda kolesterolet”) ansamlas i det innersta lagret av 
kärlväggen; detta leder till en skada på kärlet och som resultat uppstår inflammation i 
vävnaden. Vi tror oss idag veta att det är inflammationen som är den drivande faktorn i 
bildandet av och utvecklingen av aterosklerotiska plack [1, 2, 4, 6-8]. Inflammatoriska celler i 
immunsystemet kommer dra sig till området för att försöka reparera skadan; bland dessa 
celler återfinner vi makrofagerna (”storätarna”), en viktig komponent i immunsystemet som 
bl.a. verkar genom att utsöndra signalmolekyler till andra celler i immunsystemet och agera 
som en koordinator av det inflammatoriska svaret. Normalt sett är inflammationen en viktig 
del i kroppens läkningssystem, när en vävnad skadas uppstår inflammation som bidrar till att 
skadan läks och när läkning har skett klingar inflammationen av; men eftersom denna skada 
inte kan repareras kommer inflammationen att fortsätta, öka och leda till större vävnadsskada 
– inflammatoriska celler och LDL fortsätter ansamlas. Den brännande frågan i sammanhanget 
är – vad är det som driver inflammationen? Detta är en stor och komplex fråga där mycket har 
gjorts för att föra kunskapen framåt. Vi vet idag mycket om hur och varför inflammationen 
uppstår, men långt ifrån allt. Det är just denna fråga som vår studie berör. 
Vi har i denna studie funnit att det i områden av syrebrist i det humana 
aterosklerotiska placket återfinns makrofager (inflammatoriska celler) som uttrycker 
angiotensin II receptor typ 1 (AT₁). Angiotensin II och AT₁ är viktiga komponenter kroppens 
H 
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system för att reglera blodtrycket (lägg till referens); men man har också på senare tid börjat 
inse att stimulering av AT₁ med angiotensin II kan leda till inflammation (lägg till referens). 
Det skulle alltså förefalla som om makrofager i aterosklerotiska plack uttrycker AT₁ vilket 
skulle kunna bidra till inflammationen i placket. Det mest intressanta i vår upptäckt är att 
dessa makrofager som uttrycker AT₁ uppvisar tecken på syrebrist. Detta antyder att det skulle 
kunna finnas en koppling mellan syrebris och uttryck av AT₁. Något som ytterligare stödjer 
detta är att när vi utför våra analyser ser vi att uttryck av syrebristmarkören HIF-1α (hypoxia 
inducible factor-1α) korrelerar väl med förekomst av makrofager. Likaså korrelerar förekomst 
av makrofager ytterst väl med uttryck av AT₁. Detta öppnar för spännande möjligheter till ny 
forskning kring vilka effekter syrebrist och AT₁ uttryck i makrofager kan ha på inflammation 
och utvecklingen av ateroskleros. Om vi kan förstå dessa processer är det möjligt att vi kan 
lära oss att motverka dem och minska dödligheten och sjukligheten i hjärt-kärlsjukdom. 
Redan idag finns det läkemedel som blockerar AT₁; om vi kan visa att stimulering av AT₁ 
driver utveckling av ateroskleros skulle användningen av dessa läkemedel kanske komma fler 
till gagn. 
Tillvägagångssätt 
I vårt arbete har vi undersökt humana aterosklerotiska plack från frivilliga studiedeltagare 
som genomgått operation med kirurgiskt avlägsnande av plack i halskärlen. Till vårt 
förfogande hade vi 123 plack, dessa delade vi i mycket tunna snitt (4 mikrometer) som vi 
sedan färgade in med specifika antikroppar och färger för att detektera uttryck av makrofager, 
AT₁ och syrebristmarkören HIF-1α. Till varje färgning behöver man ett nytt snitt men 
eftersom snitten är så tunna blir det fortfarande samma del av placket man tittar på trots att det 
är ett nytt snitt. Efter färgning kunde vi fotografera placken i mikroskop för att sedan 
analysera dem med hjälp av ett datorprogram specialframtaget för forskningsanalys av olika 
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vävnader. Genom att inspektera de olika färgningarna för varje plack kunde vi se att AT₁ och 
syrebristmarkören HIF-1α båda uttrycks i områden där det finns rikligt med makrofager. När 
vi sedan med hjälp av vårt datorprogram gör en uträkning för att se hur mycket AT₁, HIF-1α 
och makrofager det finns i varje plack ser vi att mängden AT₁ korrelerar oerhört väl med 
mängden makrofager, ju fler makrofager desto mer AT₁. Vi ser också att mängden HIF-1α 
korrelerar väl med mängden makrofager, ju mer HIF-1α – det vill säga ju mer syrebrist – 
desto mer makrofager.  
 För att försäkra oss om att det vi ser i placken verkligen skulle kunna stämma 
undersökte vi humana makrofager som donerats av frivilliga givare och som vi placerade i 
cell odling (dvs. cellerna tas från sin naturliga miljö i kroppen och odlas i värmeskåp i 
näringsrik vätska). På dessa makrofager kunde vi sedan testa om de uttryckte AT₁ med hjälp 
av en teknik som kallas western immunoblotting, som i korthet går ut på att proteiner från 
celler separeras beroende på storlek och sedan färgas in med specifika antikroppar så att de 
kan detekteras. På detta sätt kunde vi fastslå att humana makrofager mycket riktigt uttrycker 
AT₁ och det vi observerat när vi undersökte placken skulle mycket väl kunna stämma. 
Framtiden 
Vi hoppas kunna forska vidare på vilken betydelse syrebrist, makrofager och AT₁ har för 
utvecklandet av ateroskleros. Förhoppningsvis kan även andra tänkas intressera sig för ämnet 
och hjälpa oss att undersöka detta. Visionen är givet vis att vi i framtiden skall kunna erbjuda 
bättre behandling för denna vanliga och svåra sjukdom som ateroskleros är. 
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